The new england journal of medicine

Dabigatran in Atrial Fibrillation
1.0
0.05
Cumulative Hazard Rate
0.8
0.6
0.4
0.2
0.04
0.03
0.02
0.01
Dabigatran,
110 mg
Warfarin
Dabigatran,
150 mg
0.00
0 6 12 18 24 30
No. at Risk
Warfarin
Dabigatran, 110 mg
Dabigatran, 150 mg
0.0
0 6 12 18 24 30
6022
6015
6076
5862
5862
5939
5718
5710
5779
Months
4593
4593
4682
2890
2945
3044
1322
1385
1429
Figure 1. Cumulative Hazard Rates for the AUTHOR: Primary Connolly Outcome of Stroke or RETAKE Systemic 1st Embolism, According to Treatment
Group.
ICM
REG F FIGURE: 1 of 2
2nd
3rd
CASE
Revised
EMail
Line 4-C
SIZE
H/T
Combo
AUTHOR, PLEASE NOTE:
Figure has been redrawn and type has been reset.
Please check carefully.
was associated with a trend toward ARTIST: an increased ts
Enon
risk of major bleeding (P = 0.052) and also with
increased risks of gastrointestinal, minor, and any
bleeding. The net clinical benefit was almost identical
for the two doses.
JOB: 36112 ISSUE: 09-17-09
Adverse Events and Liver Function
The only adverse effect that was significantly more
common with dabigatran than with warfarin was
dyspepsia (Table 4). Dyspepsia occurred in 348
patients (5.8%) in the warfarin group and in 707
patients (11.8%) and 688 patients (11.3%) in the
110-mg and 150-mg dabigatran groups, respectively
(P